ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 262 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,769 | +210.0% | 276,829 | +179.9% | 0.06% | +266.7% |
| Q1 2023 | $1,861 | -75.0% | 98,890 | -78.8% | 0.02% | -86.1% |
| Q4 2022 | $7,432 | -99.3% | 466,843 | +665.4% | 0.11% | +730.8% |
| Q3 2022 | $998,000 | +58.2% | 60,997 | +36.2% | 0.01% | +62.5% |
| Q2 2022 | $631,000 | -64.7% | 44,773 | -39.3% | 0.01% | -65.2% |
| Q1 2022 | $1,786,000 | +142.7% | 73,761 | +144.3% | 0.02% | +187.5% |
| Q2 2021 | $736,000 | +9.9% | 30,188 | +16.3% | 0.01% | -20.0% |
| Q1 2021 | $670,000 | -77.4% | 25,959 | -53.3% | 0.01% | -65.5% |
| Q4 2020 | $2,970,000 | +389.3% | 55,556 | +277.6% | 0.03% | +141.7% |
| Q3 2020 | $607,000 | -91.1% | 14,712 | -89.6% | 0.01% | -93.2% |
| Q2 2020 | $6,835,000 | +1864.1% | 141,006 | +1613.7% | 0.18% | +831.6% |
| Q1 2020 | $348,000 | -82.6% | 8,228 | -82.4% | 0.02% | -50.0% |
| Q4 2019 | $2,001,000 | – | 46,781 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |